
ArriVent BioPharma, Inc.: updates and filings
Price
$11.26
November 19, 2026Market cap $582M
What Ploutos Investor adds for ArriVent BioPharma
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 20% since Nov 9, 2026, when the 10-Q these figures come from was filed ($14.16 then, $11.26 on Nov 19, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
October 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operations, officer or director changeForm8-K
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 26, 2026Regulation FD disclosure, other material eventsForm8-K
- Oct 19, 2026Regulation FD disclosureForm8-K
- Oct 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 13, 2026Regulation FD disclosure, other material eventsForm8-K
- Oct 8, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Oct 6, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 12, 2026Material agreement entered, results of operationsForm8-K
- Jul 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 22, 2026Shareholder voteForm8-K
- May 11, 2026Other material eventsForm8-K
- May 11, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 11, 2026Results of operationsForm8-K
- May 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Mar 17, 2026Regulation FD disclosure, other material eventsForm8-K
- Mar 5, 2026Shares registered for employeesFormS-8
- Mar 5, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 5, 2026Results of operationsForm8-K
- Mar 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations, officer or director change | Document |
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 26, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Oct 19, 2026 | 8-K | Regulation FD disclosure | Document |
| Oct 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 13, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Oct 8, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Oct 6, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 12, 2026 | 8-K | Material agreement entered, results of operations | Document |
| Jul 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 22, 2026 | 8-K | Shareholder vote | Document |
| May 11, 2026 | 8-K | Other material events | Document |
| May 11, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 11, 2026 | 8-K | Results of operations | Document |
| May 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 17, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Mar 5, 2026 | S-8 | Shares registered for employees | Document |
| Mar 5, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 5, 2026 | 8-K | Results of operations | Document |
| Mar 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 23, 2021.
The full analysis
What do ArriVent BioPharma's filings show?
The filings are where every one of ArriVent BioPharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.